Nephrol Dial Transplant (2003) 18: 1770-1776
© 2003 European Renal Association-European Dialysis and Transplant Association
In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3
1 Fuji Gotemba Research Labs, Chugai Pharmaceutical Co., Ltd, Shizuoka and 2 Division of Nephrology & Dialysis Center, Kobe University School of Medicine, Kobe, Japan
Correspondence and offprint requests to: Masafumi Fukagawa, Division of Nephrology & Dialysis Center, Kobe University School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. Email: fukagawa{at}med.kobe-u.ac.jp
Background. Although it effectively suppresses parathyroid hormone (PTH) secretion, vitamin D [1,25(OH)2D3] therapy often causes tissue calcification over the long term. In patients on chronic dialysis, cardiovascular calcification is clearly linked to an unfavourable prognosis. In pre-dialysis patients, renal calcification of the kidney leads to the deterioration of renal function.
Methods. We compared the propensities of 22-oxacalcitriol (OCT), with lesser calcaemic action, and 1,25(OH)2D3 for producing their potential side effects in rats: (i) metastatic calcification of heart and aorta, and (ii) renal dysfunction with nephrocalcinosis, using the same effective doses for hyperparathyroidism. OCT (1.25 and 6.25 µg/kg) or 1,25(OH)2D3 (0.125 and 0.625 µg/kg) solutions were administered intravenously to subtotally nephrectomized (SNX) rats three times weekly for 2 weeks.
Results. Despite the suppression of PTH to comparable levels, the calcification of the hearts, aortas and kidneys in the 1,25(OH)2D3-treated group was significantly greater than in the OCT-treated group. Of interest was that, in the OCT (6.25 µg/kg) group, the degree of calcification in hearts, aortas and kidneys were distinctly lower than those in the 1,25(OH)2D3 (0.125 µg/kg) group despite the comparable serum Ca x Pi products. Therefore, there may be different mechanisms behind the calcifications resulting from OCT and 1,25(OH)2D3. Deterioration of renal function, tubular changes, and atypical hyperplasia of proximal tubules associated with calcification were more severe in the 1,25(OH)2D3-treated group than in the OCT-treated group.
Conclusions. These results indicate that OCT may be an effective agent for the suppression of PTH with a lesser risk of cardiovascular calcification or deterioration of residual renal function.
Keywords: Ca x Pi product; metastatic calcification; 22-oxacalcitriol; 1,25(OH)2D3
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Noonan, K. Koch, M. Nakane, J. Ma, D. Dixon, A. Bolin, and G. Reinhart Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3824 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Al-Badr and K. J. Martin Vitamin D and Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1555 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wu-Wong, W. Noonan, J. Ma, D. Dixon, M. Nakane, A. L. Bolin, K. A. Koch, S. Postl, S. J. Morgan, and G. A. Reinhart Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tamagaki, Q. Yuan, H. Ohkawa, I. Imazeki, Y. Moriguchi, N. Imai, S. Sasaki, K. Takeda, and M. Fukagawa Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia Nephrol. Dial. Transplant., March 1, 2006; 21(3): 651 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moe and N. X. Chen Pathophysiology of Vascular Calcification in Chronic Kidney Disease Circ. Res., September 17, 2004; 95(6): 560 - 567. [Abstract] [Full Text] [PDF]
|
|